Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel. This presentation is significant as it provides a platform for the company to showcase its innovative approach to oncology therapeutics to a broad audience of investors and industry experts.
The core of Kairos Pharma's strategy lies in its lead candidate, ENV-105, an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This approach is crucial because drug resistance remains one of the most formidable challenges in cancer treatment, often leading to treatment failure and disease progression.
The company's focus on structural biology to overcome drug resistance and immune suppression in cancer positions it at the forefront of precision oncology. The presentation at the H.C. Wainwright conference is expected to highlight the potential of ENV-105 and the company's pipeline, offering insights into how Kairos Pharma plans to address unmet medical needs in oncology.
The announcement comes at a time when the investment community is increasingly interested in innovative cancer therapies that can improve patient outcomes. By participating in this prestigious conference, Kairos Pharma is likely to attract attention from potential partners and investors who are keen on supporting advancements in cancer treatment.
For those interested in learning more about Kairos Pharma and its latest updates, the company's newsroom can be accessed at https://ibn.fm/KAPA. Additionally, the full press release regarding this announcement is available at https://ibn.fm/NrBQD.
Kairos Pharma is based in Los Angeles, California, and is dedicated to overcoming drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, represents a promising therapeutic approach that could potentially benefit patients who have limited options due to resistance to existing treatments.
